Background Canada’s Patented Medicine Prices Review Board (PMPRB) regulates pharmaceutical prices to prevent excessive pricing. In June 2024, the PMPRB proposed major reforms including international price comparison (IPC) screening, annual re-benchmarking of existing medicines, and new complaint processes. Understanding how stakeholders responded to these proposals reveals the competing interests and strategic positioning that shape pharmaceutical price regulation.